Increasing incidences of colorectal cancer and the development of novel CRC screening tests employing methods of genetic screening are some primary factors expected to drive market growth over the forecast period. For More Information Visit - http://www.grandviewresearch.com/industry-analysis/in-vitro-colorectal-cancer-screening-tests-market

1. In-Vitro Colorectal Cancer Screening Tests Market By
Product (Fecal Occult Blood Tests, Biomarker Tests, CRC
DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB
Agglutination Test, Panel DNA Tests) Is Expected To Reach
USD 840.5 Million In 2022
The global market for in-vitro colorectal cancer screening tests is expected to reach USD 840.5
million by 2022, according to a new study by Grand View Research, Inc. Increasing incidences
of colorectal cancer and the development of novel CRC screening tests employing methods of
genetic screening are some primary factors expected to drive market growth over the forecast
period. The implementation of government regulations introducing compulsory application of
cancer screening tests, introduction of minimally invasive tests which screen for CRC using
DNA and genomic biomarkers, and the presence of high unmet needs are expected to fuel the
growth of the in-vitro colorectal cancer screening tests market over the forecast period.
Apart from the already present genetic tests for CRC screening in the market, this segment of the
market is relatively new and still in its nascent stages. Many biomarker tests are still under
investigational research and yet others in their development phase. The major market players
have significant products related to colorectal cancer screening using biomarkers and DNA
screening in their development and approval pipelines which are expected to be fully
commercialized within the next seven years. The introduction of these novel genetic tests in the
market is expected to enhance revenue generation in the market and positively influence
penetration rates.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/in-
vitro-colorectal-cancer-screening-tests-market

2. Global In-vitro colorectal cancer screening tests market, by product, 2012-2022 (USD
Million)
Table of Content
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 In-Vitro Colorectal Cancer Screening Tests Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics
3.3.2 Market driver analysis
3.3.2.1 Growing incidence of colon and rectal cancers
3.3.2.2 Growing accuracy of colorectal cancer screening by use of genetic testing
3.3.2.3 Presence of a number of colorectal cancer screening products in pipeline
3.3.3 Market restraint analysis
3.3.3.1 Pending investigational evidence for certain genetic screening tests

3. 3.3.3.2 Difficulty to undertake CRC screening tests to encompass the entire
3.3.3.3 Lack of cancer screening guideless in Asia Pacific region
3.4 Industry Analysis - Porter’s
3.5 Key opportunities prioritized
3.6 In-Vitro Colorectal Cancer Screening Tests market - PESTEL analysis
Chapter 4 In-Vitro Colorectal Cancer Screening Tests Product Outlook
4.1 In-vitro colorectal cancer screening tests market share by test type, 2014 & 2022
4.2 Fecal Occult Blood Tests
4.2.1 Fecal occult blood tests market, 2012 - 2022 (USD Million)
4.2.2 Guaiac FOB Stool Test
4.2.2.1 Guaiac FOB stool tests market, 2012 - 2022 (USD Million)
4.2.3 Immuno-FOB agglutination test
4.2.3.1 Immuno-FOB agglutination tests market, 2012 - 2022 (USD Million)
4.2.4 Lateral Flow Immuno-FOB Test
4.2.4.1 Lateral flow Immuno-FOB tests market, 2012 - 2022 (USD Million)
4.2.5 Immuno-FOB ELISA test
4.2.5.1 Immuno-FOB ELISA tests market, 2012 - 2022 (USD Million)
4.3 Biomarker tests market
4.3.2 Tumor M2-PK Stool Test
4.3.2.1 Tumor M2-PK stool tests market, 2012 - 2022 (USD Million)
4.3.3 Transferrin assays
4.3.3.1 Transferrin assays market, 2012 - 2022 (USD Million)
4.4 CRC DNA screening tests
4.4.1 CRC DNA screening tests market, 2012 - 2022, (USD Million)
4.4.2 Methylated Gene Testing
4.4.2.1 Methylated gene testing market, 2012 - 2022 (USD Million)
4.4.3 Panel DNA Tests
4.4.3.1 Panel DNA tests market, 2012 - 2022 (USD Million)
Chapter 5 In-vitroColorectal Cancer Screening Tests Regional Outlook
5.1 In-vitro colorectal cancer screening tests market share by region, 2014 & 2022
5.2 North America
5.2.1 North America market, by product, 2012 - 2022 (USD Million)
5.2.2 U.S. market, by product, 2012 - 2022 (USD Million)
5.2.3 Canada market, by product, 2012 - 2022 (USD Million)
5.3 Europe
5.3.1 Europe market, by product, 2012 - 2022 (USD Million)
5.3.2 Germany market, by product, 2012 - 2022 (USD Million)
5.3.3 UK market, by product, 2012 - 2022 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific market, by product, 2012 - 2022 (USD Million)
5.4.2 Japan market, by product, 2012 - 2022 (USD Million)
5.4.3 China market, by product, 2012 - 2022 (USD Million)
5.5 Latin America

4. 5.5.1 Latin America market, by product, 2012 - 2022 (USD Million)
5.5.2 Brazil market, by product, 2012 - 2022 (USD Million)
5.5.3 Mexico market, by product, 2012 - 2022 (USD Million)
5.6 MEA
5.6.1 MEA market, by product, 2012 - 2022 (USD Million)
5.6.2 South Africa market, by product, 2012 - 2022 (USD Million)
Chapter 6 Competitive Landscape
6.1 Abbott Molecular Inc
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Alere Inc.
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Beckman Coulter Inc
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.4 Eiken Chemical
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Epigenomics AG Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Sysmex Corporation
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 Siemens Healthcare Ltd.
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.8 Quest Diagnostics Incorporated
6.8.1 Company Overview
6.8.2 Financial Performance

5. 6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 CompanianDx
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 OncoCyte Corporation-Biotime
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 Merck Millipore
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 GeneNews Ltd.
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 BioMarCare Technologies Ltd.
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Immunostics Inc.
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.15 Exiqon
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Kyowa Medex Co. Ltd.
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 Mode Diagnostics
6.17.1 Company Overview

6. 6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Randox Laboratories Ltd.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 R-Biopharm Incorporation
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
Browse full report @ http://www.grandviewresearch.com/industry-analysis/in-vitro-
colorectal-cancer-screening-tests-market
List of Tables
TABLE 1 In-Vitro Colorectal Cancer Screening Tests Market - Industry Summary & Key
Buying Criteria
TABLE 2 Global market, by test type, 2012 - 2022 (USD Million)
TABLE 3 Global market, by region, 2012 - 2022 (USD Million)
TABLE 4 In-Vitro Colorectal Cancer Screening Tests - Key market driver analysis
TABLE 5 In-Vitro Colorectal Cancer Screening Tests - Key market restraint analysis
TABLE 6 North America market by test type, (USD Million), 2012 - 2022
TABLE 7 North America fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 8 North America biomarker tests market, 2012 - 2022 (USD Million)
TABLE 9 North America CRA DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 10 U.S. i market by test type, 2012 - 2022 (USD Million)
TABLE 11 U.S. fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 12 U.S biomarker test market, 2012 - 2022 (USD Million)
TABLE 13 U.S. CRC DNA screening test market, 2012 - 2022 (USD Million)
TABLE 14 Canada market by test type, 2012 - 2022 (USD Million)
TABLE 15 Canada fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 16 Canada CRC DNA screening test market, 2012 - 2022 (USD Million)
TABLE 17 Canada biomarker test market, 2012 - 2022 (USD Million)
TABLE 18 Europe market by test type, 2012 - 2022 (USD Million)
TABLE 19 Europe fecal occult blood test market, 2012 - 2022 (USD Million)
TABLE 20 Europe biomarker test market, 2012 - 2022 (USD Million)
TABLE 21 Europe CRC DNA screening test market, 2012 - 2022 (USD Million)

7. TABLE 22 Germany market by test type, 2012 - 2022 (USD Million)
TABLE 23 Germany fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 24 Germany biomarker tests market, 2012 - 2022 (USD Million)
TABLE 25 Germany CRC DNA screening test, 2012 - 2022 (USD Million)
TABLE 26 UK market by test type, 2012 - 2022 (USD Million)
TABLE 27 UK fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 28 UK biomarker tests market, 2012 - 2022 (USD Million)
TABLE 29 UK CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 30 Asia Pacific market by test type, 2012 - 2022 (USD Million)
TABLE 31 Asia Pacific fecal occult blood tests, 2012 - 2022 (USD Million)
TABLE 32 Asia Pacific biomarker tests, 2012 - 2022 (USD Million)
TABLE 33 Asia Pacific CRC DNA screening tests, 2012 - 2022 (USD Million)
TABLE 34 Japan market by test type, 2012 - 2022 (USD Million)
TABLE 35 Japan fecal occult tests market 2012 - 2022 (USD Million)
TABLE 36 Japan biomarker tests market 2012 - 2022 (USD Million)
TABLE 37 Japan CRC DNA screening tests market 2012 - 2022 (USD Million)
TABLE 38 China market by test type, 2012 - 2022 (USD Million)
TABLE 39 China fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 40 China biomarker tests market, 2012 - 2022 (USD Million)
TABLE 41 China CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 42 Latin America market by test type, 2012 - 2022 (USD Million)
TABLE 43 Latin America fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 44 Latin America biomarker tests market, 2012 - 2022 (USD Million)
TABLE 45 Latin America CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 46 Brazil market by product, 2012 - 2022 (USD Million)
TABLE 47 Brazil fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 48 Brazil biomarker tests market, 2012 - 2022 (USD Million)
TABLE 49 Brazil CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 50 Mexico market by test type, 2012 - 2022 (USD Million)
TABLE 51 Mexico fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 52 Mexico biomarker tests market, 2012 - 2022 (USD Million)
TABLE 53 Mexico CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 54 MEA market by test type, 2012 - 2022 (USD Million)
TABLE 55 MEA fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 56 MEA biomarker tests market, 2012 - 2022 (USD Million)
TABLE 57 MEA CRC DNA screening tests market, 2012 - 2022 (USD Million)
TABLE 58 South Africa by test types, 2012 - 2022 (USD Million)
TABLE 59 South Africa fecal occult blood tests market, 2012 - 2022 (USD Million)
TABLE 60 South Africa biomarker tests market, 2012 - 2022 (USD Million)
TABLE 61 South Africa CRC DNA screening tests market, 2012 - 2022 (USD Million)
For More Information visit http://www.grandviewresearch.com/industry-analysis/in-vitro-
colorectal-cancer-screening-tests-market

8. List of Figures
FIG. 1 In-vitro colorectal cancer screening tests: Market segmentation
FIG. 2 Global market, (USD Million), 2012 - 2022
FIG. 3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics
FIG. 4 In-Vitro Colorectal Cancer Screening Tests market - Porter’s Analysis
FIG. 5 Key opportunities prioritized, 2014
FIG. 6 In-vitro colorectal cancer screening tests market - PESTEL analysis
FIG. 7 In-vitro colorectal cancer screening tests market share by test type, 2014 & 2022
FIG. 8 Global fecal occult blood tests market, 2012 - 2022 (USD Million)
FIG. 9 Global guaiac FOB stool tests market, 2012 - 2022 (USD Million)
FIG. 10 Immuno-FOB agglutination tests market, 2012 - 2022 (USD Million)
FIG. 11 Lateral flow immuno-FOB tests market, 2012 - 2022 (USD Million)
FIG. 12 Immuno-FOB ELISA tests market, 2012 - 2022 (USD Million)
FIG. 13 Global biomarker tests market, 2012 - 2022 (USD Million)
FIG. 14 Tumor M2-PK stool tests, 2012 - 2022 (USD Million)
FIG. 15 Transferrin assays market, 2012 - 2022 (USD Million)
FIG. 16 Global CRC DNA screening tests market, 2012 - 2022 (USD Million)
FIG. 17 Methylated gene testing market, 2012 - 2022 (USD Million)
FIG. 18 Panel DNA tests market, 2012 - 2022 (USD Million)
FIG. 19 In-vitro colorectal cancer screening tests market share by region, 2014 & 2022
FIG. 20 North America market, 2012 - 2022 (USD Million)
FIG. 21 U.S. in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 22 Canada in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 23 Europe in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 24 Germany in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 25 UK in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 26 Asia Pacific in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 27 Japan in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 28 China in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 29 Latin America In-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 30 Brazil in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 31 Mexico In-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 32 MEA in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
FIG. 33 South Africa in-vitro colorectal cancer screening tests, 2012 - 2022 (USD Million)
Further key findings from the study suggest:
 The in-vitro colorectal cancer screening tests market was found to be dominated by fecal
occult blood tests owing to their higher usage rates and easy applicability to large groups
of population at once for cancer screening.

9. The more conventional guaiac FOB stool test, even though still occupy a significant share
of the market, are expected to lose market share to their counterpart FOB tests which
involve immunological testing along with the conventional testing.
 The investigation and development of newer more accurate methods for colorectal cancer
screening have led to the development of biomarker and DNA screening tests. Tumor
M2-PK Stool test is currently the most widely used screening test among biomarker and
DNA screening tests and is expected to gain revenue share over the forecast period.
 North America accounted for the largest share of the in-vitro colorectal cancer screening
tests market in 2014 owing to high incidences of colorectal cancer and presence of a large
base of geriatric population in the region.
 Europe accounted for a significant market share in 2014 owing to the presence of high
cancer prevalence levels in the region. Colorectal cancer is the second most common
cancer in both men and women after lung and breast cancer. Commission of the
European Communities has estimated that 500 million screening examinations are
expected to be conducted for colorectal and cervical cancer in the publicly mandated
programmes in EU from 2010 to 2020.
 Key participants of the in-vitro colorectal cancer screening tests market include Randox
Laboratories, Sysmex, Immunostics, Beckman Coulter, Abbott Molecular, Epigenomics,
Alere, Siemens Healthcare, Eiken Chemical, Kyowa Medex, Quest Diagnostics,
Oncocyte, Companion Dx, Merck Millipore, ExiQon, Mode Diagnostics, and R-
Biopharm.
Request free sample of this Report @ http://www.grandviewresearch.com/industry-
analysis/in-vitro-colorectal-cancer-screening-tests-market/request
For the purpose of this study, Grand View Research has segmented the in-vitro colorectal cancer
screening tests market on the basis of product and region:
Global In-Vitro Colorectal Screening Tests Market, Product Outlook (Revenue, USD
Million, 2012 - 2022)
 Fecal Occult Blood Tests
 Guaiac FOB Stool Test
 Immuno-FOB Agglutination Test
 Lateral Flow Immuno-FOB Test
 Immuno-FOB ELISA Test
 Biomarker Tests
 Tumor M2-PK Stool Test
 Transferrin Assays
 CRC DNA Screening Tests

10.  Methylated Gene Testing
 Panel DNA Tests
In-Vitro Colorectal Screening Tests Market, Regional Outlook (Revenue, USD Million,
2012 - 2022)
 North America
 U.S.
 Canada
 Europe
 Germany
 UK
 Asia Pacific
 Japan
 China
 Latin America
 Brazil
 Mexico
 MEA
 South Africa
Browse All Reports of this category @
http://www.grandviewresearch.com/industry/clinical-diagnostics
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-the-
shelf, customized research reports and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and energy. With a deep-
seated understanding of varied business environments, Grand View Research provides strategic
objective insights.

11. Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Website: Grand View Research
Blog Site: http://www.divog.org/